Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.56 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | AKT2 | P31751 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CCR3 | P51677 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13569909 | 0.83 | NCF1 (0.58) | NCF1CXCR4PRMT3CARM1PRMT6 | |
| SCHEMBL22732993 | 0.82 | PRMT3 (0.41) | NCF1PRMT3CARM1PRMT6PRMT1 | |
| SCHEMBL1540650 | 0.79 | NCF1 (0.60) | NCF1CXCR4PRMT3CARM1PRMT6 | |
| SCHEMBL9343697 | 0.79 | NCF1 (0.54) | NCF1CXCR4PRMT3CARM1PRMT6 | |
| SCHEMBL103579 | 0.79 | NCF1 (0.54) | NCF1CXCR4PRMT3CARM1PRMT6 | |
| SCHEMBL8435896 | 0.79 | NCF1 (0.38) | NCF1PRMT3CARM1PRMT6PRMT1 | |
| SCHEMBL7137670 | 0.79 | NCF1 (0.48) | NCF1CXCR4PRMT3CARM1PRMT6 | |
| SCHEMBL2803853 | 0.78 | GNAI3 (0.50) | NCF1PRMT3CARM1PRMT6PRMT1 | |
| SCHEMBL14890554 | 0.77 | NCF1 (0.56) | NCF1CXCR4PRMT3CARM1PRMT6 | |
| Hydrochloric Acid SCHEMBL2293794 | 0.76 | GNAI3 (0.53) | PRMT3CARM1PRMT6PRMT1PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105873920-B | As 5-HT4The indazole compound of receptor stimulating agent | 苏文生命科学有限公司 | 2018-06-08 | — | — | CN | disclosed |
| US-9951045-B2 | Indazole compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| US-9951045-B2 | Indazole compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| US-9951045-B2 | Indazole compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2018-04-24 | — | — | US | disclosed |
| EP-3099675-B1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2018-02-14 | — | — | EP | disclosed |
| EP-3099675-B1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2018-02-14 | — | — | EP | disclosed |
| EP-3099675-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Suven Life Sciences Limited (IN) | 2016-12-07 | — | — | EP | disclosed |
| US-20160311797-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-10-27 | — | — | US | disclosed |
| US-20160311797-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-10-27 | — | — | US | disclosed |
| US-20160311797-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-10-27 | — | — | US | disclosed |
| CN-105873920-A | Indazole compounds as 5-HT4 receptor agonists | 苏文生命科学有限公司 | 2016-08-17 | — | — | CN | disclosed |
| WO-2015092804-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015092804-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-06-25 | — | — | WO | disclosed |
| EP-2536716-B1 | AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-21 | — | — | EP | disclosed |
| US-8426604-B2 | Aminothiazolones as estrogen related receptor-alpha modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-04-23 | — | — | US | disclosed |
| EP-2536716-A1 | AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103130-A1 | AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | WO | disclosed |
| US-20110200586-A1 | AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311797-A1 | INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | NCF1 4170/4885CXCR4 705/4885PRMT3 946/4885 |
| US-20110200586-A1 | AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, ESRRG | NCF1 3889/4885CXCR4 1544/4885PRMT3 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.